Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q4 2022 Earnings Conference Call February 22, 2023 5:00 PM ET

Company Participants

Debra Hart - Head of Investor Relations

Carl Hull - Interim Chief Executive Officer

Kevin Herde - Chief Financial Officer

Trey Martin - President of Biologic Safety Testing

Becky Buzzeo - Chief Commercial Officer

Conference Call Participants

Dan Leonard - Credit Suisse

Matthew Sykes - Goldman Sachs

Daniel Arias - Stifel

Catherine Schulte - Robert W. Baird

Tejas Savant - Morgan Stanley

Operator

Greetings, and welcome to the Fourth Quarter and Year-end 2022 Maravai LifeSciences Earnings Conference Call. [Operator Instructions] Please note that this conference is being recorded.

I will now turn the conference over to our host, Debra Hart, Head of Investor Relations. Thank you. You may begin.

Debra Hart

Thank you, Diego. Good afternoon, everyone. Thanks for joining us for our fourth quarter and year-end 2022 earnings call. Our press release and the slides that accompany today's call are posted on our website and are available at investors.maravai.com.

As you can see on our agenda for today on Slide 2, Carl will first provide you with a business update, and Kevin will review our financial results and guidance. Trey Martin, President of Biologic Safety Testing; and Becky Buzzeo, our Chief Commercial Officer, will join the call for the question-and-answer session following the prepared remarks.

We remind you management will make forward-looking statements and refer to GAAP and non-GAAP financial measures during today's call. It is possible that actual results could differ from management's expectations. We refer you to Slide 3 for more detail on forward-looking statements and our use of non-GAAP financial measures. Our just issued press release provides reconciliations to the most directly comparable GAAP measures. Please also refer to Maravai's SEC filings for additional information on the risks and uncertainties that may impact our operating results, performance and financial condition.

Now I'll turn the call over to Carl.

Carl Hull

Well, thank you, Deb, and good afternoon, everyone. We appreciate having you join us for our call today. Let's start with our fourth quarter results on Slide 5. Today, we reported $205 million in revenue for the quarter, and our adjusted EBITDA of $130 million led to adjusted earnings per share of $0.35 per share. Our base business revenue of $81 million marks a record revenue quarter, up 67% over the fourth quarter of 2021, demonstrating the continued widespread uptake of messenger RNA platform technologies across multiple therapeutic infectious disease vaccine and immuno-oncology programs.